| P50 | author | Angela Tincani | Q73304219 |
| P2093 | author name string | Paolo Airò | |
| | Enrico Colombo | |
| | Mirko Scarsi | |
| | Silvia Piantoni | |
| P2860 | cites work | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update | Q26859134 |
| | A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 |
| | Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry | Q34276905 |
| | Smoking and rheumatoid arthritis. | Q34834289 |
| | Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis | Q38071773 |
| | Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins | Q43415346 |
| | Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load | Q43779427 |
| | Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry | Q45803075 |
| | Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry | Q46065201 |
| | Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis | Q46068649 |
| | Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks | Q50448991 |
| | Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. | Q50858925 |
| | Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. | Q51886503 |
| | Predictors of response to anti-TNF- therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register | Q57751361 |
| | Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e | Q63101754 |
| | Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis | Q84637125 |
| | CD8+ T cell profiles in patients with rheumatoid arthritis-the effects of costimulation blockade: comment on the article by Carvalheiro et al | Q87242295 |
| P433 | issue | 4 | |
| P304 | page(s) | 1065-1069 | |
| P577 | publication date | 2016-01-26 | |
| P1433 | published in | Clinical Rheumatology | Q15754927 |
| P1476 | title | Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis. | |
| P478 | volume | 35 | |